The synergistic interaction between the calcineurin B subunit and IFN-γ enhances macrophage antitumor activity

Cell Death and Disease

Volumn 6, Issue 5, 2015, Pages

  Su, Z ^a,b,c   Yang, R ^a   Zhang, W ^a   Xu, L ^a   Zhong, Y ^a   Yin, Y ^a   Cen, J ^a   Dewitt, J P ^c   Wei, Q ^a  

^a BEIJING NORMAL UNIVERSITY   (China)

^b SOUTHEAST UNIVERSITY   (China)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ALPHA INTEGRIN; CALCINEURIN; CALCINEURIN B SUBUNIT; CASPASE 3; CD86 ANTIGEN; CXCL9 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INDUCIBLE NITRIC OXIDE SYNTHASE; INTEGRIN ALPHAM; INTERFERON REGULATORY FACTOR 1; INTERFERON REGULATORY FACTOR 9; INTERLEUKIN 12; JANUS KINASE 2; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE C DELTA; SMALL INTERFERING RNA; STAT1 PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; CD11B ANTIGEN; RECOMBINANT PROTEIN; STAT1 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL ISOLATION; COCULTURE; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MACROPHAGE; MELANOMA; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL INOCULATION; TUMOR INVASION; TUMOR VOLUME; WEIGHT REDUCTION; ANIMAL; C57BL MOUSE; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; PHOSPHORYLATION; RANDOMIZATION; RAW 264.7 CELL LINE;

ANIMALS; ANTIGENS, CD11B; CALCINEURIN; HUMANS; INTERFERON-GAMMA; MACROPHAGES; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; RANDOM ALLOCATION; RAW 264.7 CELLS; RECOMBINANT PROTEINS; STAT1 TRANSCRIPTION FACTOR;

EID: 84952320786     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2015.92     Document Type: Article

References (64)

1. Crabtree GR. Generic signals and specific minireview outcomes: signaling through Ca2+, calcineurin, and NF-AT. Cell 1999;96:611-614.
2. Manalan AS, Klee CB. Activation of calcineurin by limited proteolysis. Proc Natl Acad Sci 1983;80:4291-4295.
3. Clipstone N, Crabtree G. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 1992;357:695.
4. Malleret G, Haditsch U, Genoux D, Jones MW, Bliss T V P, Vanhoose AM et al. Inducible and reversible enhancement of learning, memory, and long-term potentiation by genetic inhibition of calcineurin. Cell 2001;104:675-686.
5. Jurado S, Biou V, Malenka RC. A calcineurin/AKAP complex is required for NMDA receptordependent long-term depression. Nat Neurosci 2010;13:1053-1055.
6. Wang HG, Pathan N, Ethell IM, Krajewski S, Yamaguchi Y, Shibasaki F et al. Ca2+-induced apoptosis through calcineurin dephosphorylation of BAD. Science 1999;284:339.
7. Wang JX, Jiao JQ, Li Q, Long B, Wang K, Liu JP et al. miR-499 regulates mitochondrial dynamics by targeting calcineurin and dynamin-related protein-1. Nat Med 2010;17:71-78.
8. Sussman MA, Lim HW, Gude N, Taigen T, Olson EN, Robbins J et al. Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science 1998;281:1690-1693.
9. Heineke J, Auger-Messier M, Correll RN, Xu J, Benard MJ, Yuan W et al. CIB1 is a regulator of pathological cardiac hypertrophy. Nat Med 2010;16:872-879.
10. Shi L, Jackstadt R, Siemens H, Li H, Kirchner T, Hermeking H. p53-Induced miR-15a/16-1 and AP4 form a double-negative feedback loop to regulate epithelial-mesenchymal transition and metastasis in colorectal cancer. Cancer Res 2014;74:532-542.
11. Neilson JR, Winslow MM, Hur EM, Crabtree GR. Calcineurin B1 is essential for positive but not negative selection during thymocyte development. Immunity 2004;20:255-266.
12. Heit JJ, Apelqvist AA, Gu X, Winslow MM, Neilson JR, Crabtree GR et al. Calcineurin/NFAT signalling regulates pancreatic β-cell growth and function. Nature 2006;443:345-349.
13. Li W, Handschumacher RE. Identification of two calcineurin B-binding proteins: tubulin and heat shock protein 60. Biochim Biophys Acta 2002;1599:72-81.
14. Saeki M, Irie Y, Ni L, Itsuki Y, Terao Y, Kawabata S et al. Calcineurin potentiates the activation of procaspase-3 by accelerating its proteolytic maturation. J Biol Chem 2007;282:11786.
15. Li N, Zhang Z, Zhang W, Wei Q. Calcineurin B subunit interacts with proteasome subunit alpha type 7 and represses hypoxia-inducible factor-1a activity via the proteasome pathway. Biochem Biophys Res Commun 2011;405:468-472.
16. Li J, Guo JX, Su ZY, Hu ML, Liu W, Wei Q. Calcineurin subunit B activates dendritic cells and acts as a cancer vaccine adjuvant. Int Immunol 2011;23:327.
17. ® HBV vaccine adjuvant. Vaccine 2012;30:4719-4727.
18. Liu L, Su Z, Xin S, Cheng J, Li J, Xu L et al. The calcineurin B subunit (CnB) is a new ligand of integrin αM that mediates CnB-induced Apo2L/TRAIL expression in macrophages. J Immunol 2012;188:238-247.
19. Su Z, Xin S, Xu L, Cheng J, Guo J, Li L et al. The calcineurin B subunit induces TNF-related apoptosis-inducing ligand (TRAIL) expression via CD11b-NF-κB pathway in RAW264. 7 macrophages. Biochem Biophys Res Commun 2012;417:777-783.
20. Wei Q, Lian ML, Jing FZ, Zhang N, Yan MS, Chen Y et al. Studies of calcineurin B subunit from genetic engineering for use in medicine. Drug Dev Res 2002;56:40-43.
21. Schoenborn JR, Wilson CB. Regulation of interferon-γ during innate and adaptive immune responses. Adv Immunol 2007;96:41-101.
22. Tu SP, Quante M, Bhagat G, Takaishi S, Cui G, Yang XD et al. IFN-γ inhibits gastric carcinogenesis by inducing epithelial cell autophagy and T-cell apoptosis. Cancer Res 2011;71:4247.
23. Peng W, Liu C, Xu C, Lou Y, Chen J, Yang Y et al. PD-1 blockade enhances t cell migration to tumors by elevating IFN-γ inducible chemokines. Cancer Res 2012;72:5209-5218.
24. Luth S, Schrader J, Zander S, Carambia A, Buchkremer J, Huber S et al. Chronic inflammatory IFN-γ signaling suppresses hepatocarcinogenesis in mice by sensitizing hepatocytes for apoptosis. Cancer Res 2011;71:3763-3771.
25. Ngiow SF, von Scheidt B, Akiba H, Yagita H, Teng M W L, Smyth MJ. Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors. Cancer Res 2011;71:3540-3551.
26. Takeda K, Nakayama M, Sakaki M, Hayakawa Y, Imawari M, Ogasawara K et al. IFN-γ production by lung NK cells is critical for the natural resistance to pulmonary metastasis of B16 melanoma in mice. J Leukoc Biol 2011;90:777-785.
27. Frucht DM, Fukao T, Bogdan C, Schindler H, O'Shea JJ, Koyasu S. IFN-γ production by antigen-presenting cells: mechanisms emerge. Trends Immunol 2001;22:556-560.
28. Menard C, Blay JY, Borg C, Michiels S, Ghiringhelli F, Robert C et al. Natural killer cell IFN-γ levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. Cancer Res 2009;69:3563-3569.
29. Durbin JE, Hackenmiller R, Simon MC, Levy DE. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 1996;84:443-450.
30. Goh KC, Haque SJ, Williams B R G. p38 MAP kinase is required for STAT1 serine phosphorylation and transcriptional activation induced by interferons. EMBO J 1999;18:5601-5608.
31. Kovarik P, Stoiber D, Eyers PA, Menghini R, Neininger A, Gaestel M et al. Stress-induced phosphorylation of STAT1 at Ser727 requires p38 mitogen-activated protein kinase whereas IFN-γ uses a different signaling pathway. Proc Natl Acad Sci 1999;96:13956.
32. Deb DK, Sassano A, Lekmine F, Majchrzak B, Verma A, Kambhampati S et al. Activation of protein kinase Cδ by IFN-γ. J Immunol 2003;171:267-273.
33. Wen Z, Zhong Z, Darnell JE. Maximal activation of transcription by Statl and Stat3 requires both tyrosine and serine phosphorylation. Cell 1995;82:241-250.
34. Zhang X, Blenis J, Li HC, Schindler C, Chen-Kiang S. Requirement of serine phosphorylation for formation of STAT-promoter complexes. Science 1995;267:1990-1994.
35. Ouchi T, Lee SW, Ouchi M, Aaronson SA, Horvath CM. Collaboration of signal transducer and activator of transcription 1 (STAT1) and BRCA1 in differential regulation of IFN-γ target genes. Proc Natl Acad Sci 2000;97:5208.
36. Zhang JJ, Zhao Y, Chait BT, Lathem WW, Ritzi M, Knippers R et al. Ser727-dependent recruitment of MCM5 by Stat1α in IFN-γ-induced transcriptional activation. EMBO J 1998;17:6963-6971.
37. Gollob JA, Schnipper CP, Murphy EA, Ritz J, Frank DA. The functional synergy between IL-12 and IL-2 involves p38 mitogen-activated protein kinase and is associated with the augmentation of STAT serine phosphorylation. J Immunol 1999;162:4472-4481.
38. Dalpke AH, Eckerle S, Frey M, Heeg K. Triggering of Toll-like receptors modulates IFN-β signaling: involvement of serine 727 STAT1 phosphorylation and suppressors of cytokine signaling. Eur J Immunol 2003;33:1776-1787.
39. Kovarik P, Stoiber D, Novy M, Decker T. Stat1 combines signals derived from IFN-γ and LPS receptors during macrophage activation. EMBO J 1998;17:3660-3668.
40. Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 2010;22:231-237.
41. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010;141:39-51.
42. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumorassociated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002;23:549-555.
43. Shaykhiev R, Krause A, Salit J, Strulovici-Barel Y, Harvey B-G, O'Connor TP et al. Smokingdependent reprogramming of alveolar macrophage polarization: implication for pathogenesis of chronic obstructive pulmonary disease. J Immunol 2009;183:2867-2883.
44. Movahedi K, Laoui D, Gysemans C, Baeten M, Stangé G, Van den Bossche J et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C (high) monocytes. Cancer Res 2010;70:5728-5739.
45. Rolny C, Mazzone M, Tugues S, Laoui D, Johansson I, Coulon C et al. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 2011;19:31-44.
46. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011;331:1612-1616.
47. Kota RS, Rutledge JC, Gohil K, Kumar A, Enelow RI, Ramana CV. Regulation of gene expression in RAW 264.7 macrophage cell line by interferon-γ. Biochem Biophys Res Commun 2006;342:1137-1146.
48. Majumder S, Zhou L Z H, Chaturvedi P, Babcock G, Aras S, Ransohoff RM. p48/STAT-1α-containing complexes play a predominant role in induction of IFN-γ-inducible protein, 10 kDa (IP-10) by IFN-γ alone or in synergy with TNF-α. J Immunol 1998;161:4736.
49. Clarke N, Jimenez-Lara AM, Voltz E, Gronemeyer H. Tumor suppressor IRF-1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL. EMBO J 2004;23:3051-3060.
50. Saura M, Zaragoza C, Bao C, McMillan A, Lowenstein CJ. Interaction of interferon regulatory factor-1 and nuclear factor kappa B during activation of inducible nitric oxide synthase transcription1. J Mol Biol 1999;289:459-471.
51. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-γ: an overview of signals, mechanisms and functions. J Leukoc Biol 2004;75:163-189.
52. Kovarik P, Stoiber D, Novy M, Decker T. Stat1 combines signals derived from IFN-γ and LPS receptors during macrophage activation. EMBO J 1998;17:3660-3668.
53. Gutterman JU. Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci USA 1994;91:1198.
54. George S, Hutson TE, Mekhail T, Wood L, Finke J, Elson P et al. Phase I trial of PEGinterferon and recombinant IL-2 in patients with metastatic renal cell carcinoma. Cancer Chemother Pharmacol 2008;62:347-354.
55. Marth C, Windbichler G, Hausmaninger H, Petru E, Estermann K, Pelzer A et al. Interferongamma in combination with carboplatin and paclitaxel as a safe and effective first-line treatment option for advanced ovarian cancer: results of a phase I/II study. Int J Gynecol Cancer 2006;16:1522-1528.
56. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010;28:2137-2143.
57. Guiducci C, Vicari AP, Sangaletti S, Trinchieri G, Colombo MP. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res 2005;65:3437-3446.
58. Pickert G, Lim HY, Weigert A, Häussler A, Myrczek T, Waldner M et al. Inhibition of GTP cyclohydrolase attenuates tumor growth by reducing angiogenesis and M2-like polarization of tumor associated macrophages. Int J Cancer 2012;132:591-604.
59. Nakanishi Y, Nakatsuji M, Seno H, Ishizu S, Akitake-Kawano R, Kanda K et al. COX-2 inhibition alters the phenotype of tumor-associated macrophages from M2 to M1 in ApcMin/+ mouse polyps. Carcinogenesis 2011;32:1333-1339.
60. Cai X, Yin Y, Li N, Zhu D, Zhang J, Zhang C-Y et al. Re-polarization of tumor-associated macrophages to pro-inflammatory M1 macrophages by microRNA-155. J Mol Cell Biol 2012;4:341-343.
61. Wang Y-C, He F, Feng F, Liu X-W, Dong G-Y, Qin H-Y et al. Notch signaling determines the M1 versus M2 polarization of macrophages in antitumor immune responses. Cancer Res 2010;70:4840-4849.
62. Scott MJ, Billiar TR. β2-integrin-induced p38 MAPK activation is a key mediator in the CD14/TLR4/MD2-dependent uptake of lipopolysaccharide by hepatocytes. J Biol Chem 2008;283:29433-29446.
63. Padma S, Subramanyam C. Extracellular calcineurin: identification and quantitation in serum and amniotic fluid. Clin Biochem 1999;32:491-494.
64. Sierra JR, Corso S, Caione L, Cepero V, Conrotto P, Cignetti A et al. Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages. J Exp Med 2008;205:1673-1685.